Related Experiment Videos
Safety profile of fluvastatin
1Department of Clinical Research and Development, Sandoz Pharma Ltd, Basel, Switzerland.
British Journal of Clinical Practice. Supplement
|January 1, 1996
Summary
Fluvastatin, a statin drug, demonstrates good tolerability and safety in patients with hyperlipidemia. Adverse events are infrequent and comparable to placebo, with no increased risk of myopathy or rhabdomyolysis.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
Background:
- Statins are widely used lipid-modifying agents known for good tolerability.
- Older lipid-lowering drugs often have poor patient compliance.
- Fluvastatin is a newer statin evaluated in numerous hyperlipidemia patients.
Purpose of the Study:
- To assess the safety and tolerability profile of fluvastatin.
- To compare fluvastatin's adverse event incidence with placebo and other lipid-modifying agents.
Main Methods:
- Controlled clinical studies involving patients with hyperlipidemia.
- Evaluation of adverse events, including gastrointestinal disturbances, liver enzyme elevations, and creatine kinase levels.
- Assessment of myopathy, rhabdomyolysis, and drug interactions.
Main Results:
- Most adverse events with fluvastatin were not higher than placebo.
- Gastrointestinal disturbances were common to all statins but less frequent than with cholestyramine or fibrates.
- Liver transaminase elevations and creatine kinase elevations led to discontinuation at rates similar to placebo.
- No drug-related myopathy or rhabdomyolysis were reported; myalgia incidence was similar to placebo.
- Fluvastatin did not interfere with antihypertensive efficacy.
- Overall discontinuation rates due to adverse events were comparable to placebo.
Conclusions:
- Fluvastatin exhibits a favorable safety profile, comparable to placebo.
- It is well-tolerated in patients with hyperlipidemia, with a low incidence of significant adverse events.
- Fluvastatin offers a safe and effective option for lipid modification.